3162
D. HABIBI AND M. NASROLLAHZADEH
R ¼ 4-NO2 in Scheme 1 and Table 1, Entry 3. IR (KBr, cmꢀ1) : 3390, 3300,
3125, 1637, 1588, 1517, 1490, 1341, 1291, 1258, 1125, 1090, 1069, 1048, 872, 863, 855,
840, 746, 689; 1H NMR (500 MHz, acetone): isomer A: d 5.94 (1H, d, br), 7.77 (2H,
d, J ¼ 9.2 Hz), 8.14 (2H, d, J ¼ 9.2 Hz), 9.16 (1H, s, br); 13C NMR (125 MHz,
1
DMSO-d6): isomer A: d 116.8, 125.1, 140.3, 147.1, 155.0; H NMR (500 MHz, acet-
one): isomer B: d 6.58 (2H, s, br), 8.01 (2H, d, J ¼ 7.2 Hz), 8.49 (2H, d, J ¼ 7.2 Hz);
13C NMR (125 MHz, DMSO-d6): isomer B: d 124.6, 125.3, 138.6, 146.9, 155.4.
R ¼ 4-(OMe) in Scheme 2 and Table 1, Entry 4. IR (KBr): 3425, 3300,
3130, 2985, 2975, 2830, 1645, 1575, 1545, 1505, 1339, 1290, 1249, 1167, 1080,
1
1015, 834, 817, 629, 610, 551 cmꢀ1; H NMR (500 MHz, DMSO-d6) isomer A: d
3.67 (3H, s), 5.70 (1H, s), 6.78 (2H, d, J ¼ 8.7 Hz), 7.26 (2H, d, J ¼ 8.7 Hz), 8.33
(1H, s); 13C NMR (125 MHz, DMSO-d6) isomer A: d 55.1, 113.8, 119.4, 133.7,
1
153.9, 156.2; H NMR (500 MHz, DMSO-d6) isomer B: d 3.81 (3H, s), 6.73 (2H,
s), 7.11 (2H, d, J ¼ 8.7 Hz), 7.45 (2H, d, J ¼ 8.7 Hz); 13C NMR (125 MHz, DMSO-
d6) isomer B: d 55.6, 114.9, 126.0, 126.1, 155.1, 159.7.
R ¼ 2,4-(Me)2 in Scheme 2 and Table 1, Entry 5. IR (KBr): 3425, 3300,
3010, 2900, 1649, 1619, 1590, 1537, 1524, 1507, 1352, 1312, 1263, 1223, 1132,
1
1034, 825, 799, 758, 653, 614, 555 cmꢀ1; H NMR (500 MHz, DMSO-d6) isomer
A: d 2.15 (3H, s), 2.21 (3H, s), 5.92 (1H, s), 6.89 (1H, d, J ¼ 8.0 Hz), 6.93 (1H, s),
7.60 (1H, d, J ¼ 8.0 Hz), 7.61 (1H, s, br); 13C NMR (125 MHz, DMSO-d6) isomer
A: d 17.8, 20.3, 121.4, 126.4, 127.4, 130.5, 130.9, 135.5, 156.3; 1H NMR
(500 MHz, DMSO-d6) isomer B: d 2.01 (3H, s), 2.38 (3H, s), 6.68 (2H, s), 7.21
(1H, d, J ¼ 8.0 Hz), 7.24 (1H, d, J ¼ 8.0 Hz), 7.29 (1H, s); 13C NMR (125 MHz,
DMSO-d6) isomer B: d 16.8, 20.7, 127.3, 127.7, 129.5, 131.8, 134.9, 140.1, 155.7.
R ¼ 4-Me in Scheme 2 and Table 1, Entry 6. IR (KBr): 3415, 3304, 3145,
2980, 2915, 1648, 1589, 1568, 1542, 1514, 1118, 1092, 1087, 842, 811 cmꢀ1 1H
;
NMR (300 MHz, DMSO-d6) isomer A: d 2.19 (3H, s), 5.74 (1H, s), 6.99 (2H, d,
J ¼ 8.2 Hz), 7.25 (2H, d, J ¼ 8.2 Hz), 8.37 (1H, s); 13C NMR (75 MHz, DMSO-d6)
1
isomer A: d 20.3, 117.8, 123.9, 130.2, 138.1, 154.9; H NMR (300 MHz, DMSO-
d6) isomer B: d 2.38 (3H, s), 6.80 (2H, s), 7.39 (2H, d, J ¼ 8.1 Hz), 7.43 (2H, d,
J ¼ 8.1 Hz); 13C NMR (75 MHz, DMSO-d6) isomer B: d 20.7, 128.9, 129.6, 130.9,
138.9, 156.2.
RESULTS AND DISCUSSION
The general synthetic method is depicted in Scheme 2. Arylaminotetrazoles 3–8
were obtained from the reaction of cyanamides 1 with sodium azide 2 in the presence
of FeCl3-SiO2 as a heterogeneous catalyst at 110 ꢁC for appropriate time in excellent
yields, as summarized in Table 1.
We have studied the cycloaddition reaction of cyanamides with sodium azide
in the presence of PPh3, LiCl, and FeCl3-SiO2 (Table 2). Results show that in
all cases the products were obtained in good yields. However, PPh3 and LiCl,
being homogeneous reagents, could not be recycled from the reaction mixture. In
contrast to the reaction conditions with PPh3 and LiCl, FeCl3-SiO2 is a cheap and
nonhazardous solid acid catalyst that can be handled easily and is important from